South Korea-U.S. Free Trade Agreement Likely To Put Stranglehold On Local Korean Drug Makers
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korean pharmaceutical companies are bracing for a tough time ahead if the governments of South Korea and the U.S. ratify a long-awaited Free Trade Agreement hammered out last year after eight rounds of negotiations between the two countries
You may also be interested in...
Merck Signs Wide-Ranging MOU To Help Beef Up Korea's Global R&D Capabilities
SEOUL - Merck & Co. Inc. has signed a memorandum of understanding with South Korea to invest KRW 210 billion ($192.9 million) in the country for research and development of new drugs, including manpower exchanges, Korea's Ministry of Health and Welfare said
Merck Signs Wide-Ranging MOU To Help Beef Up Korea's Global R&D Capabilities
SEOUL - Merck & Co. Inc. has signed a memorandum of understanding with South Korea to invest KRW 210 billion ($192.9 million) in the country for research and development of new drugs, including manpower exchanges, Korea's Ministry of Health and Welfare said
U.S. And South Korean Presidents Say More Negotiation Needed To Ratify Free Trade Agreement But Pharma Provisions Seen Intact
SEOUL - Although South Korean President Lee Myung-bak and U.S. President Barack Obama last week hinted at the possibility of more talks or a partial revision of their bilateral Free Trade Agreement in the U.S. Congress, pharma provisions outlined in the FTA aren't likely to be a bone of contention